modelR03AC19

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Olodaterol
ATC code:R03AC19
route:inhalation
compartments:2
dosage:5mg
volume of distribution:1110L
clearance:872L/h
other parameters in model implementation

Olodaterol is a long-acting beta2-adrenergic agonist (LABA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is inhaled, offering bronchodilation lasting 24 hours, and is approved for use in many countries.

Pharmacokinetics

Pharmacokinetics in healthy adult subjects after inhaled administration of olodaterol; parameters represent typical population values following repeat dosing of 5 micrograms once daily via the Respimat inhaler.

References

  1. Borghardt, JM, et al., & Kloft, C (2016). Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. British journal of clinical pharmacology 81(3) 538–552. DOI:10.1111/bcp.12780 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26348533

  2. Borghardt, JM, et al., & Kloft, C (2016). Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. British journal of clinical pharmacology 82(3) 739–753. DOI:10.1111/bcp.12999 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27145733

  3. Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75(6) 665–673. DOI:10.1007/s40265-015-0371-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773742

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)